Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or Ustekinumab
JAMA Dermatology · 01.12.2025 · 161 (12) · 1289
DOI: 10.1001/jamadermatol.2025.3928 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, erschienen am 01.12.2025. Verfasst von Christopher Willy Schwarz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This cohort study estimates 5-year standardized risks for any first cancer among patients being treated with biologics for moderate to severe psoriasis.
Autor:innen und Institutionen
- Department of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Copenhagen Research Group for Inflammatory Skin, Herlev and Gentofte Hospital, Copenhagen, Denmark.
- Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
- Health Institute, Aarhus University, Aarhus, Denmark.
Zitieren
APA
Schwarz, C. W., Rasmussen, M. K., Bertelsen, T., Iversen, L., Skov, L., & Loft, N. (2025). Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or Ustekinumab. JAMA Dermatology, 161(12), 1289. https://doi.org/10.1001/jamadermatol.2025.3928
Vancouver
Schwarz CW, Rasmussen MK, Bertelsen T, Iversen L, Skov L, Loft N. Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or Ustekinumab. JAMA Dermatology. 2025;161(12):1289. doi:10.1001/jamadermatol.2025.3928
BibTeX
@article{Schwarz2025,
author = {Schwarz, Christopher Willy and Rasmussen, Mads Kirchheiner and Bertelsen, Trine and Iversen, Lars and Skov, Lone and Loft, Nikolai},
title = {Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or Ustekinumab},
journal = {JAMA Dermatology},
year = {2025},
volume = {161},
number = {12},
pages = {1289},
doi = {10.1001/jamadermatol.2025.3928}
}
EUVIMED